June 4 2024 is an important date for MDMA-Assisted Therapy
The FDA is currently in the final stages of the MDMA-Assisted Therapy approval process, with the decision expected in August 2024. The next stage in the approval process is the meeting of the FDA Advisory Committee on June 4 to review Lykos Therapeutics’ application.
“MDMA Therapy Training at TheraPsil” with Yasmeen deRosenroll – MDMA THERAPY PODCAST #21
TheraPsil is a Canadian West Coast non-profit, best known for their pioneering work with Psilocybin-Assisted Therapy for end-of-life anxiety, as well as their incredible national advocacy efforts. Recently, TheraPsil added MDMA-Assisted Therapy Training to their roster of offerings. Join us for a conversation with Yasmeen de Rosenroll, TheraPsil’s Director of Training and Operations.
“Rachel Nuwer: History of MDMA″ – MDMA THERAPY PODCAST #20
Rachel Nuwer is a science journalist. Her new book “I Feel Love” is to-date the most comprehensive account of the history of MDMA. Rachel paints numerous stories about various colorful people related to the history of MDMA.
“Pamela Kryskow: And the Psychedelic Re-emergence″ – MDMA THERAPY PODCAST #19
Dr. Pamela Kryskow is a powerful force reshaping the Canadian psychedelic scene. In this episode, she talks about various psychedelic initiatives she helped co-create, including a progressive non-profit Roots to Thrive Psychedelic Assisted Therapy, the Psychedelic Association of Canada, the first Canadian post-graduate certificate in psychedelic therapies, and the largest-ever psilocybin microdosing study with over 33,000 participants.
<strong>Will MDMA-Assisted Therapy for PTSD be approved in 2024?</strong>
Below is a reprint of a major news release from MAPS, an organization that was solely responsible for the FDA MDMA-Assisted Therapy research.
MAPS PBC No Longer a Public Benefit Corporation
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been admirably resistant to the pressures of the market economy for a long time. But the capital have won, again, and in a somewhat sad move, MAPS’s pharmaceutical arm, the MAPS Public Benefit Corporation, has now become a conventionally structured pharmacological company called Lykos Pharmaceutical.
Rick Doblin is 70
Rick Doblin just turned 70, and I am writing this blog post to share my appreciation and respect for this man.
“Safety: MDMA-Assisted Therapy 101″ with Darek Dawda – MDMA THERAPY PODCAST #18
In this third part of the MDMA-Assisted Therapy series, Dr. Darek Dawda reviews numerous topics related to safety. He argues that, given the nature of this therapy, extra emphasis on safety is of utmost importance, and that some aspects of safety, such as what happens after the dosing sessions, require much more attention than they have received to date. The importance of extended Informed Consent is emphasized.
MAPS just filed an FDA application for MDMA-Assisted Therapy for PTSD – and ETI is starting an MDMA-AT training groups for local Health Care Professionals
After years-long research journey, MAPS PBC just filed an FDA application for the
approval of MDMA-assisted therapy for PTSD. This is the first such application for any
Psychedelic-Assisted Therapy!!!
“MDMA Assisted Therapy 2024” with Rick Doblin – MDMA THERAPY PODCAST #17
Darek Dawda in conversation with Rick Doblin, a legendary visionary who founded MAPS, and who is just about to make one of the most effective known psychotherapies legally available for medical therapeutic use. Rick talks about his journey, the power of MDMA-Assisted Therapy, his thoughts on the future of humankind, and much more.
